Back in 2014, on the BBC’s Sunday Politics London programme, Andrew Neil was discussing David Cameron’s plan to curb EU migration, a plan driven more by fear than common sense.
Nick Watt, then of The Guardian and now of BBC Newsnight, offered a clear and prescient warning.
“The biggest challenge facing the NHS is two million extra people aged over 70 by 2020.
“How are you going to pay for that? You’re going to pay for that by having young people working and earning taxes.
“And who’s that? It’s immigrants.”
That was also the time Nigel Farage was gaining traction with his poisonous claim that Britain had too many migrants. And it was the time the then Prime Minister, David Cameron, was bending to Farage’s rhetoric by promising fewer EU migrants.
As we now know, Britain needed every one of those EU migrants, and many more besides. The truth was clear even then.
Yet the pro-immigration argument wasn’t properly made in 2014, just as it isn’t being properly made today. If it had been communicated clearly, we could have punctured Farage’s populist nonsense long before the referendum.
We could have avoided the lies that poisoned public debate. We could have avoided Brexit.
Instead, the lies won, and now the architect of Brexit is attempting yet another comeback.
For the avoidance of doubt, Britain needs migrants because we have a growing ageing population, a low birth rate, and far more jobs than we have people to do them.
This is not a complicated message. But because it has never been properly explained, xenophobia has been allowed to flourish and Britain has lost its way.
The post The message Britain ignored: Why we need migrants appeared first on Ideas on Europe.
Written by Laurence Amand-Eeckhout.
Human Immunodeficiency Virus (HIV) infection remains a major public health challenge across the EU and the world. There is a broad consensus at European and international level that, to achieve the goal of ending AIDS as a public-health threat by 2030, efforts must be scaled up on prevention, education, providing widespread testing access, early diagnosis, and access to both preventive and curative care for all, without discrimination.
BackgroundBy attacking the immune system, HIV weakens the body’s defence against other infections and diseases. The most advanced stage of HIV infection is AIDS (acquired immune deficiency syndrome). Found in a variety of an infected person’s body fluids, including blood, semen, vaginal secretions and breast milk, HIV can be transmitted through sex, blood transfusion, the sharing of contaminated needles, and between mother and child during pregnancy, childbirth and breastfeeding. It is not, however, spread by kissing, hugging, shaking hands, or sharing personal objects, food or water. Anyone at high risk of getting HIV can take pre-exposure prophylaxis (PrEP) medicine to prevent or at least reduce the risk of HIV infection.
People diagnosed with HIV and treated early can now expect to live for a normal or almost normal lifespan. Infections can be treated to prevent progression to AIDS, by decreasing viral load in an infected body (antiretroviral therapy, ‘ART’). However, ART does not cure HIV infection, and no vaccine exists.
The United Nations Programme on HIV/AIDS (UNAIDS) is leading the global effort to end the AIDS epidemic by 2030, as part of the Sustainable Development Goals (SDGs) adopted in 2015 (Goal 3.3).
World AIDS Day, proclaimed by the United Nations in 1988, is marked every year on 1 December. This year’s theme ‘Overcoming disruption, transforming the AIDS response‘ highlights that after decades of progress, the HIV response stands at a crossroads. Severe funding cuts are disrupting life-saving prevention services and many communities face heightened risks and vulnerabilities, threatening decades of progress.
Facts and figuresUNAIDS data show that, in 2024, 1.3 million people worldwide contracted HIV (compared to 3.4 million people in 1996), 40.8 million people were living with HIV (39.4 million adults – aged 15 or older – and 1.4 million children), and 630 000 people died of AIDS-related illnesses.
According to the 2025 report on ‘HIV/AIDS surveillance in Europe’ (2024 data), published on 27 November 2025 jointly by the European Centre for Disease Prevention and Control (ECDC) and the WHO Regional Office for Europe, 2.6 million people have been reported with HIV in the WHO European region (made up of 53 countries covering a vast geographical region from the Atlantic to the Pacific Ocean), including over678 000 people in the EU/European Economic Area (EEA). In the EU/EEA specifically, over 24 000 people were newly diagnosed with HIV in 2024, representing a slight 5.7 % decrease compared to 2023 (over 25 000), resulting in a rate of 5.3 per 100 000 people.
In addition, about 1 in 14 people living with HIV in the EU/EEA are still unaware of their status, which contributes to late diagnosis, worse health outcomes, and the continued transmission of HIV. Across the EU/EEA, almost half (48.0 %) of HIV diagnoses are made late, leading to higher morbidity and an increased risk of AIDS-related death.
EU actionUnder Article 168 of the Treaty on the Functioning of the EU, Member States are responsible for their own healthcare policies and systems. However, the EU can play a supporting role and add value to national action. EU action focuses on prevention and support for people living with HIV. Projects funded under the EU4Health programme (e.g. CORE and European testing week) aim at reducing inequalities and provide support for vulnerable groups (including migrants), such as easier access to information, testing, and community-based services. The EU drugs strategy seeks to ensure a high level of health protection, including measures to reduce drug-related infectious diseases such as HIV. The European Commission is expected to present a new drugs strategy on 3 December 2025. Since the early years of the AIDS epidemic in the 1980s, the EU has invested significantly in research. Horizon Europe supports projects ranging from basic research to the development and testing of new treatments and vaccines. The European Medicines Agency (EMA) contributes to the global HIV response through scientific evaluation, supervision and monitoring of medicine safety. This includes support to help Member States to achieve the UN SDG Goal 3.3 target. In that context, the Commission facilitates the exchange of best practice through the Health Security Committee and dedicated networks on the EU Health Policy Platform.
The ECDC provides Member States with guidance, for example on preventing HIV transmission through substances of human origin and among people who inject drugs. It also publishes reports summarising progress. In its November 2025 report, the ECDC notes that although progress has been made towards achieving UN SDG 3.3 to end AIDS as a public threat by 2030, the EU/EEA remains off track for some targets, notably those related to prevention, testing and treatment. While the number of HIV infections and HIV-related deaths have declined over the last decade, current trends indicate that stronger efforts in prevention, testing and treatment are needed to reach the 2025 and 2030 incidence and mortality targets. Many countries lacked data for some monitoring indicators, making comprehensive assessment difficult.
As highlighted in its 2022 global health strategy, on the world stage the EU supports the Global Fund in its efforts against HIV, malaria and tuberculosis. Since 2002, the Commission has disbursed €3.5 billion to the Global Fund and has pledged €715 million for 2023-2025, complementing contributions from the EU Member States. The Global Fund’s Eighth Replenishment Summit took place on 21 November 2025 in Johannesburg (South Africa). Partners around the world pledged US$11.34 billion for 2026-2028; the European Commission and some countries have yet to pledge.
European Parliament positionParliament has played a leading role in promoting stronger and coordinated HIV/AIDS policies, advocating for comprehensive prevention, a strong human‑rights based approach and the reduction of inequalities in access to HIV services inside and outside the EU. This commitment was reflected in its May 2021 resolution on accelerating progress and tackling inequalities towards ending AIDS as a public health threat by 2030. In its December 2023 resolution on non-communicable diseases, Parliament called for further research into the development of vaccines and innovative treatment options against HIV, and for Member States to step up efforts to ensure timely testing, diagnosis and access to high quality care, including for vulnerable groups. Throughout the current legislative term, Members have submitted several written questions to the Commission, notably on fighting HIV and AIDS, on restriction of USAID funding for health programmes and, more recently, on the Commission contribution to the 2025 global fund replenishment.
To mark World AIDS Day 2025, the Vice-President of the European Parliament, Victor Negrescu (S&D, Romania), is organising a high-level conference on 10 December 2025 entitled ‘EU at a crossroads: lifespan and gender equity in the HIV response’.
Read this ‘at a glance’ note on ‘Combating HIV/AIDS: Progress and EU action‘ in the Think Tank pages of the European Parliament.
L'écrivaine roumaine Ioana Pârvulescu est l'invitée du club de lecture Cosmose pour évoquer son oeuvre dont le roman La vie commence vendredi (Seuil, 2016), paru en français.
Samedi 29 novembre 2025 à 16 heures à la Maison de la vie associative (93, rue Saint-Dominique 75007 Paris)
Présentation du roman Le Garçon de l'avenue des Martyrs (Ginkgo, 2025),
en présence de l'auteur.
Samedi 29 novembre à 19 heures
à la librairie Volontaires (3, rue des Volontaires 75015 Paris)